By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genocea Biosciences 

100 Acorn Park Drive

Cambridge  Massachusetts  02140  U.S.A.
Phone: 617-876-8191 Fax: 617-876-8192


Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases.

Genocea’s pipeline includes programs addressing genital herpes, pneumococcus, chlamydia, malaria and cancer immunotherapy. We currently have two products in Phase 2 clinical development:

• GEN-003, an immunotherapy to treat patients with genital herpes. We reported positive top-line data from an ongoing Phase 2b dose optimization trial from the immediate post dosing 28-day observation period in May 2015. We identified an improved dose of 60µg per protein/75µg of adjuvant, which demonstrated a highly statistically significant reduction (p>0.0001) from baseline in the viral shedding rate (55%) and genital lesion rate (60%). Data from the six-month and 12-month observation periods in this trial is expected in the fourth quarter of 2015 and the first quarter of 2016, respectively.

Data from the prior Phase 1/2a trial was the first time a therapeutic vaccine candidate has demonstrated significant reductions in the rates of viral shedding and genital lesions in genital herpes patients.

• GEN-004, a universal vaccine which is in Phase 2 development to prevent infections caused by all serotypes of pneumococcus. We have completed enrollment in a Phase 2 human challenge clinical trial and expect to report top-line data in the fourth quarter of 2015.

In a prior Phase 1 study, GEN-004 met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces.

Key Statistics

Ownership: Public

Web Site: Genocea
Symbol: GNCA

Company News
Genocea (GNCA) Reports Second Quarter 2017 Financial Results 8/9/2017 12:53:20 PM
Genocea (GNCA) Reports Positive Top-Line 12-Month Phase IIb Data For GEN-003 In Genital Herpes 7/24/2017 11:05:35 AM
Genocea (GNCA) Added To Russell 3000 And Russell 2000 Indices 6/26/2017 9:50:40 AM
Genocea (GNCA) Reports First Quarter 2017 Financial Results And Positive Clinical Developments On Lead Candidate GEN-003 In Genital Herpes 5/4/2017 11:02:21 AM
Genocea (GNCA) To Host First Quarter 2017 Financial Results Conference Call & Webcast On May 4, 2017 At 9 A.M. ET 4/27/2017 11:18:26 AM
Genocea (GNCA) Awarded World Vaccine Congress 2017 Industry Excellence Award For Best Therapeutic Vaccine For GEN-003 For Genital Herpes 4/12/2017 8:34:19 AM
Genocea (GNCA) Announces Positive 6-Month Results From GEN-003 Phase 2b Clinical Trial 1/5/2017 1:57:06 PM
Genocea (GNCA)'s Genital Herpes Candidate Successful in Mid-Stage Trial 9/29/2016 6:55:29 AM
3 Life Sciences Companies Heading Into Orbit or On the Launching Pad 4/13/2016 6:53:08 AM
Genocea (GNCA) Stock Doubles After Market Yesterday on Positive 12 Months Genital Herpes Data 3/31/2016 12:55:02 PM